According to KemPharm's latest financial reports the company has a price-to-book ratio of 2.34.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2022-12-31 | 1.85 | -23.05% |
2021-12-31 | 2.40 | -413.46% |
2020-12-31 | -0.7652 | 313.21% |
2019-12-31 | -0.1852 | -73.82% |
2018-12-31 | -0.7074 | -31.46% |
2017-12-31 | -1.03 | -55.34% |
2016-12-31 | -2.31 | -91.87% |
2015-12-31 | -28.4 | |
2014-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Theravance Biopharma
TBPH | 2.16 | -7.39% | Cayman Islands |
Jazz Pharmaceuticals JAZZ | 1.89 | -19.19% | ๐ฎ๐ช Ireland |
ANI Pharmaceuticals ANIP | 3.01 | 28.77% | ๐บ๐ธ USA |
Agile Therapeutics
AGRX | -0.1742 | -107.46% | ๐บ๐ธ USA |